Previous 10 | Next 10 |
On June 17, shares of CureVac (NASDAQ: CVAC) plunged by over 50% during the trading session after the company announced its mRNA coronavirus vaccine candidate CVnCoV had achieved just 47% overall efficacy in preventing COVID-19 during the second interim analysis of a pivotal phase...
Christian Kaspar-Bartke/Getty Images News This week, CureVac (CVAC) shocked investors and scientists alike by announcing a drastically low efficacy rate for its messenger-RNA-based COVID-19 shot from a large global trial. Compared to the ~95% efficacy rate shown by established mRNA-...
Thomas Faull/iStock via Getty Images The World Health Organization ((WHO)) warns that the Delta variant of COVID-19 first identified in India is becoming a dominant variant of the disease worldwide. "The Delta variant is well on its way to becoming the dominant variant globally because of its...
Gainers: Geron (GERN) +22%, AnPac Bio-Medical Science (ANPC) +20%, CureVac (CVAC) +13%, Crinetics Pharmaceuticals (CRNX) +7%, Seres Therapeutics (MCRB) +7%.Losers: Orphazyme (ORPH) -41%, Athira Pharma (ATHA) -41%, Chinook Therap...
CAI International (CAI) +46% on merger deal with Mitsubishi HC Capital.Sykes Enterprises (SYKE) +30% on being acquired by Sitel group for $54.0 per share.AnPac Bio-Medical Science (ANPC) +22% after securing first disease treatment patent in U.S.Geron Corporation (GERN) +20% ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! It’s the final day of trading for the week and we’re kicking it off right with a look at the pre-market stock movers for Friday! Source: ventdusud / Shutterstock.com But before we get int...
CureVac has spent a lot of time in its public statements talking about the variants that its trial ran into and saying that these are the reason for the lower efficacy. The real-world protection that we're seeing in mRNA-vaccinated populations simply does not reflect an underlying eff...
Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) aren't the only mRNA coronavirus vaccine makers in town. In fact, another company has been gaining ground -- and reported pivotal trial results this week. I'm talking about German biotech CureVac (NASDAQ: CVAC) . Even...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Another day, another rush of news in the stock market. As investors prep for the weekend they have a lot on their mind — they are watching FDA decisions , electric vehicle mishaps and crypto trading updates. So with...
A low dosage strength may be the reason why CureVac's (CVAC) COVID-19 vaccine demonstrated efficacy of 47% in a trial, Reuters reported.The study's lead author, Peter Kremsner of University Hospital in Tuebingen, Germany, told the news service that the poor efficacy was "very likely...
News, Short Squeeze, Breakout and More Instantly...
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent ...
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone pa...
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA tec...